Market Intelligence, Clinical Progress, and High-Purity Reagents for Stratifin (14-3-3 sigma) Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for SFN drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | SFN Recombinant Protein High purity (>95%), Endotoxin Controlled (<1.0 EU/μg). Sequence Verified. Suitable for PPI screening. |
View SFN Products |
| Gene Delivery | SFN Promise-ORF / Lentivirus Full-length ORF for stable cell line generation and overexpression validation. |
View SFN Products |
| Benchmark Ab | Anti-SFN Recombinant Antibody Recombinant positive control for ELISA, Western Blot, and Flow Cytometry. |
View SFN Products |
| Validator | SFN siRNA Set Target-specific knockdown verification in phenotypic and functional assays. |
View SFN Products |
| Related Target A | YWHAZ 14-3-3 family isoform (zeta) required for selectivity and off-target cross-screening. |
View YWHAZ Products |
| Related Target B | TP53 Tumor suppressor p53, a critical upstream regulator and functional partner of SFN. |
View TP53 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Isoform Selectivity (14-3-3 family) | High-purity YWHAZ and other 14-3-3 isoform proteins available for counter-screening panels. |
| Conformational Integrity for PPI | Sequence Verified, E. coli and HEK293 expressed SFN options with theoretical MW confirmed by Mass Spec. |
| Lack of Controls | Recombinant Benchmark Antibodies included for assay standardization. |
| False Positives in Knockdown | Sequence-optimized siRNA sets included for target-specific validation. |
Live SFN R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for SFN therapeutics is intensifying, with major players shifting focus from traditional mAbs to small molecule protein-protein interaction (PPI) modulators and targeted protein degraders (PROTACs). As first-generation therapies reach the clinic, the next wave of R&D is targeting SFN-mediated cell cycle arrest and its role in extracellular vesicle (EV) signaling in the tumor microenvironment.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule PPI Inhibitors | Academic Spin-offs, Biotech | Lung Squamous Cell Carcinoma | High-purity SFN recombinant proteins for FP, SPR, and MST assays. |
| PROTACs / Degraders | Targeted Therapeutics Specialists | Breast Cancer, Solid Tumors | SFN protein and target-specific siRNA for degradation kinetic validation. |
| Lentiviral Overexpression | Gene Therapy Labs | Neurodegenerative Disorders | High-titer SFN Lentiviral particles for stable cell line construction. |